Promising Advances in HER2-Positive Breast Cancer Treatment
Kazia Therapeutics Limited (NASDAQ: KZIA), a company dedicated to oncology drug development, has recently announced groundbreaking findings from a collaborative research initiative. The research, led by Professor Sudha Rao at QIMR Berghofer, focuses on the promising effects of paxalisib, a novel PI3K–mTOR inhibitor, specifically for patients grappling with Stage IV HER2-positive breast cancer.
This innovative ex vivo study involved examining blood samples from patients diagnosed with metastatic breast cancer (mBC) to determine the impact of paxalisib treatment on their metastatic presence. Impressively, findings revealed a statistically significant reduction in single circulating tumor cells as well as complete disruption of circulating tumor cell (CTC) clusters containing three or more cells.
Significance of the Findings
HER2-positive breast cancer, which represents about 15-20% of cases, poses significant treatment challenges. Despite the advancements of HER2-targeted therapies, some patients still face resistance, recurrence, or metastasis. Therefore, the need for new therapeutic strategies has become increasingly vital. Immunotherapy has seen some success in various solid tumors; however, its effectiveness in HER2-positive cases remains limited.
The Role of Paxalisib
The liquid biopsy profiling performed in this study unveiled that paxalisib succeeds in disrupting both single cells and clusters of circulating tumor cells, recognized as indicators of aggressive disease and metastasis. The immunofluorescence analyses further fortified these claims, indicating that blood samples treated with paxalisib exhibited complete disruption of highly metastatic CTC clusters that consist of three or more cells.
Dr. John Friend, CEO of Kazia Therapeutics, expressed enthusiasm regarding the results: "This monotherapy ex vivo result extends our understanding of paxalisib's potential beyond triple-negative breast cancer into the HER2-positive realm. The capacity to target and disrupt CTC clusters, which correlate with poor prognosis and metastasis, reveals a transformative therapeutic pathway. We’re excited about utilizing biomarkers in a precision medicine approach to monitor metastatic burdens and inform treatment decisions. This underscores Kazia's mission to broaden paxalisib's applicability in addressing significant unmet needs for patients faced with limited options."
Future Directions for Research
The promising findings align with Kazia's ongoing clinical trial efforts, including a Phase 1b study targeting Stage IV triple-negative breast cancer (TNBC) patients. Initial data from this trial highlighted significant declines in circulating tumor cells and clusters, suggesting that paxalisib’s benefits extend across multiple breast cancer subtypes, including HER2-positive cases.
Upcoming Presentations
As part of the future research trajectory, detailed datasets on metastatic signatures and the effects of disrupted progenitor populations in Stage IV HER2-positive breast cancer will soon be presented at a prominent global oncology meeting in the forthcoming year.
About Kazia Therapeutics
Kazia Therapeutics Limited is a dedicated drug development firm concentrated on oncology, based in Sydney, Australia. Its foremost program is paxalisib, an investigational agent designed to penetrate the brain and inhibit the PI3K / Akt / mTOR signaling pathway, aiming to treat various cancer types. Since being licensed from Genentech in late 2016, paxalisib has been involved in ten clinical trials. A Phase 2/3 study concerning glioblastoma (GBM-Agile) concluded in recent years, with plans continuing toward an essential registrational study for achieving standard approval.
Further, Kazia is engaged in ongoing trials for advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, showing positive interim results in several instances. Paxalisib has received multiple designations from the FDA as an orphan drug, denoting its potential importance.
Alongside paxalisib, Kazia is also innovating with EVT801, a small molecule targeting VEGFR3, which was acquired from Evotec SE in 2021. Preclinical studies signify EVT801's effectiveness against various tumors, supporting synergies with immuno-oncology therapies. In addition, a Phase I study has been concluded, with its preliminary findings presented at a recent ovarian cancer research symposium.
Frequently Asked Questions
What is the significance of the study regarding paxalisib?
The study highlights how paxalisib effectively disrupts aggressive tumor cell clusters, representing a potential breakthrough in treating HER2-positive breast cancer.
How does HER2-positive breast cancer differ from other types?
HER2-positive breast cancer accounts for a portion of breast cancer cases and often faces unique treatment challenges despite existing therapies.
What are circulating tumor cells (CTCs)?
CTCs are cells that break away from a primary tumor and circulate in the bloodstream, often indicating metastatic cancer progression.
What is Kazia’s role in cancer drug development?
Kazia focuses on developing innovative oncology drugs, particularly through the research and advancement of compounds like paxalisib.
What future studies does Kazia intend to pursue?
Kazia is set to present detailed findings on metastatic signatures and therapeutic impacts at an upcoming global oncology conference, emphasizing their commitment to innovative cancer treatment.
